Discovery Metabolomics & Lipidomics Fact Sheet

At Sapient, we believe that drugs can be developed much faster, cheaper, and more effectively through biomarker-driven drug discovery. We also believe extensive biomarker insights lie beyond the genome, in dynamic metabolites and lipids that read-out health, disease, and drug response over time.

That is why we have developed technologies and approaches to enable rapid, broad profiling of these small molecule chemistries, enabling discovery metabolomics and lipidomics at an entirely new speed and scale.

Learn how our rapid liquid chromatography-mass spectrometry (rLC-MS) systems capture thousands of small molecule biomarkers per sample, across thousands of samples at a time, and how our biocomputational framework supports robust identification, validation, and translational of key biomarkers that can accelerate your drug development programs.